Q3 EPS Estimates for Upstream Bio Lowered by William Blair

Key Points

• William Blair has revised its Q3 2025 earnings estimate for Upstream Bio, reducing it from ($0.70) to ($0.78) per share, while the full-year earnings estimate is projected at ($4.30) per share.
• Upstream Bio reported a quarterly EPS of ($0.74), missing analysts' expectations of ($0.61), but achieved a revenue of $0.94 million, surpassing the consensus estimate of $0.32 million.
• Despite the lowered earnings estimates, Wall Street Zen upgraded Upstream Bio from a "sell" to a "hold" rating, with the stock receiving an average rating of "Moderate Buy" and a consensus price target of $56.50.

Upstream Bio, Inc. (NASDAQ:UPB - Free Report) - Stock analysts at William Blair reduced their Q3 2025 earnings per share estimates for Upstream Bio in a report issued on Wednesday, August 6th. William Blair analyst M. Phipps now expects that the company will earn ($0.78) per share for the quarter, down from their previous estimate of ($0.70). The consensus estimate for Upstream Bio's current full-year earnings is ($4.30) per share. William Blair also issued estimates for Upstream Bio's Q4 2025 earnings at ($0.81) EPS, FY2025 earnings at ($2.84) EPS, Q1 2026 earnings at ($0.82) EPS, Q2 2026 earnings at ($0.69) EPS, Q3 2026 earnings at ($0.62) EPS, FY2026 earnings at ($2.67) EPS, FY2027 earnings at ($2.36) EPS, FY2028 earnings at ($2.47) EPS and FY2029 earnings at ($2.64) EPS.

Upstream Bio (NASDAQ:UPB - Get Free Report) last released its quarterly earnings results on Wednesday, August 6th. The company reported ($0.74) earnings per share for the quarter, missing analysts' consensus estimates of ($0.61) by ($0.13). Upstream Bio had a negative net margin of 3,836.58% and a negative return on equity of 35.90%. The firm had revenue of $0.94 million for the quarter, compared to analysts' expectations of $0.32 million.

Separately, Wall Street Zen upgraded Upstream Bio from a "sell" rating to a "hold" rating in a research report on Friday, June 6th. One research analyst has rated the stock with a hold rating and four have assigned a buy rating to the stock. According to data from MarketBeat, the company presently has an average rating of "Moderate Buy" and a consensus target price of $56.50.

Upstream Bio Trading Up 1.0%

NASDAQ UPB traded up $0.16 during trading hours on Friday, reaching $16.00. 214,758 shares of the stock traded hands, compared to its average volume of 455,531. The stock has a 50 day simple moving average of $12.04 and a two-hundred day simple moving average of $9.65. Upstream Bio has a 1 year low of $5.14 and a 1 year high of $29.46.

Institutional Inflows and Outflows

Large investors have recently modified their holdings of the stock. Corebridge Financial Inc. bought a new stake in Upstream Bio during the 4th quarter valued at approximately $142,000. JPMorgan Chase & Co. bought a new stake in Upstream Bio during the 4th quarter valued at approximately $786,000. Geode Capital Management LLC purchased a new position in Upstream Bio in the 4th quarter worth approximately $5,973,000. Wells Fargo & Company MN purchased a new position in Upstream Bio in the 4th quarter worth approximately $149,000. Finally, FMR LLC purchased a new position in Upstream Bio in the 4th quarter worth approximately $117,977,000.

Upstream Bio Company Profile

Upstream Bio, Inc, a clinical-stage biotechnology company, develops treatments for inflammatory diseases that focuses on severe respiratory disorders. It develops verekitug, a monoclonal antibody that targets and inhibits the thymic stromal lymphopoietin receptor. The company also develops therapies to treat severe asthma, chronic rhinosinusitis with nasal polyps, and chronic obstructive pulmonary disease.